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Abstract—Many diseases cause significant changes to the con-
centrations of small molecules (a.k.a. metabolites) that appear in a
person’s biofluids, which means such diseases can often be readily
detected from a persons metabolic profile.This information can
be extracted from a person’s biofluids using NMR spectroscopy.
Today, this is often done manually by trained experts, which
means this process is relatively slow, expensive and can be error-
prone. A system that can quickly, accurately and autonomously
produce a person’s metabolic profile would enable efficient and
reliable prediction of many such diseases from a single sample,
which could significantly improve the way medicine is practiced.
This paper presents such a system: Given a 1D 1H NMR
spectrum of a complex biofluid such as serum or CSF, our
BAYESIL system can automatically determine this metabolic
profile, and do so without any human guidance. This requires
first performing all of the required spectral processing steps
(i.e., Fourier transformation, phasing, solvent-removal, chemical
shift referencing, baseline correction, lineshape convolution) then
matching this resulting spectrum against a reference compound
library, which contains the signatures of each relevant metabolite.
Many of these processing steps are novel algorithms, and our
matching step views spectral matching as an inference problem
within a probabilistic graphical model that rapidly approximates
the most probable metabolic profile.
Our extensive studies on a diverse set of complex mixtures
(real biological samples, defined mixtures and realistic computer
generated spectra; each involving ∼ 50 compounds), show that
BAYESIL can autonomously and accurately find NMR-detectable
metabolites at concentrations as low as 2µM, in terms of both
identification (∼ 90% correct) and quantification (∼ 10% error),
in under 5 minutes on a single CPU processor. These results
demonstrate that BAYESIL is the first fully-automatic publicly-
accessible system that provides quantitative NMR spectral pro-
filing effectively – with an accuracy that meets or exceeds the
performance of highly trained human experts. We anticipate this
tool will usher in high-throughput metabolomics and enable a
wealth of new applications of NMR in clinical settings. Users
can access BAYESIL at http://www.bayesil.ca.
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Metabolomics is a relatively new branch of “omics” science
that focuses on the system-wide characterization of metabo-
lites [1]. Metabolomics is often viewed as complementary to the
other “omics” fields as it provides information about both an or-
ganism’s phenotype and its environment. Because metabolomics
provides a unique window on gene-environment interactions, it
is playing an increasingly important role in many quantitative
phenotyping and functional genomics studies [2], [3], [4]. It is also
finding more applications in disease diagnosis, biomarker discov-
ery and drug development/discovery (e.g., [5], [6], [7]). This rapid
growth in interest and excitement surrounding metabolomics
is also revealing its “Achilles heel”: Unlike proteomics, ge-
nomics or transcriptomics, which are high-throughput sciences,
metabolomics is a relatively low-throughput science. Compared to
genomics, where it is now possible to automatically characterize
1000s of genes, 100s of thousands of transcripts and millions of
SNPs in mere minutes, metabolomics only allows users to identify
and measure a few dozen metabolites after many hours of manual
effort. In other words, metabolomics is not automated. This prob-
lem may stem from the history of metabolomics, as its analytical
techniques, such as NMR spectroscopy, gas-chromatography-
mass spectrometry (GC-MS) and liquid chromatography-mass
spectrometry (LC-MS), were originally developed for identifying
and quantifying pure compounds, not complex mixtures. Because
most biological samples contain hundreds of metabolites, the
resulting NMR, HPLC or LC-MS spectra usually contain hundreds
or even thousands of peaks. The challenge in metabolomics,
therefore, is to identify the mixture of compounds that produced
this forest of peaks. This compound identification process, called
spectral profiling, involves fitting the mixture spectrum to a
set of individual pure reference spectra obtained from known
compounds [8], [9]. If done correctly, the fitting process yields not
only the identity of the compounds, but also the concentration
of those compounds. Therefore, the end result of a successful
spectral profiling study is a table of metabolite names and their
absolute or relative concentrations. Because spectral profiling
is such a complex pattern recognition problem, it is often best
done by a trained expert. However, this reliance on manual data
analysis by a human expert is problematic, as it is slow and
leads to inconsistent results, operator errors and reduced levels
of reproducibility [10].
The automation bottleneck in metabolomics is widely recog-
nized, and has led to a number of efforts to accelerate or automate
compound identification and/or quantification in LC-MS, in GC-
MS and in NMR spectroscopy. Some of the most active efforts in
(semi)automated compound identification and quantification have
been in NMR-based metabolomics. In particular, several software
packages have been developed that support semi-automatic NMR
spectral profiling of 1D and 2D 1H NMR spectra, including some
commercial packages (e.g., [12], [14], [13]). There are tremen-
dous differences in the quantification/identification capabilities,
spectral database size, speed and instrument compatibility of
these software tools. Furthermore, these packages either require
manual fitting or manual spectral processing, or a bit of both;
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Fig. 1. This figure shows the crowded region (3.5-4.1 PPM) of a computer generated spectrum with 150 compounds (solid black) and the fit produced by
BAYESIL (dashed red) as well as individual clusters as quantified by BAYESIL. Each cluster is free to shift a specified amount, which is at least 0.025 PPM.
see Appendix I for a comprehensive list of NMR softwares and
their limitations. The need for such manual interventions leads
to a number of issues, including slower throughput, operator
fatigue and associated operator errors, the need for highly trained
and dedicated experts, the requirement of two or more spectral
assessments for quality assessment and control purposes, and
inconsistent results between individuals, between labs or over
different time periods [8], [10].
It would be better to have a software system that can
automatically perform both spectral processing and spectral
deconvolution, be able to analyze complex mixtures (∼60 com-
pounds) quickly and accurately, and be able to produce reliable
compound concentrations. Here we describe such a system, called
BAYESIL.
Extensive testing, on computer-generated and laboratory-
generated chemical mixtures as well as real biological samples,
shows that BAYESIL consistently performs with ∼ 90% accuracy
for compound identification in mixtures with up to 60 different
metabolites. It also determines metabolite concentrations with
∼ 10% error. For computer-generated biofluid spectra, where the
ground truth is known, BAYESIL consistently outperforms highly
trained experts in both identification and quantification. BAYESIL
appears to be the first system that supports fully automated and
fully quantitative NMR-based metabolomics. This paper describes
this system, its underlying algorithms and its performance across
various tests.
I. METABOLIC PROFILING PIPELINE
BAYESIL performs fully automated spectral processing and
spectral profiling for 1D 1H NMR spectra collected on either
Agilent/Varian or Bruker instruments, at several different fre-
quencies. In particular, it uses a variety of intelligent phasing
and baseline correction methods to automatically process raw 1D
NMR spectra (i.e., FIDs). It also uses approximate inference tech-
niques to rapidly perform very accurate spectral deconvolution,
yielding both compound identities and their concentrations. Here
we briefly describe BAYESIL’s spectral processing algorithms, the
principles and rationale behind BAYESIL’s spectral deconvolution
method and the construction of BAYESIL’s spectral library.
A. Spectral Processing in BAYESIL
Successful NMR spectral profiling depends critically on the
quality and uniformity of the starting NMR spectrum. Unfortu-
nately, most spectral processing functions (i.e., phasing, baseline
correction, solvent filtering, chemical shift referencing) are left
to the user. Given the complexity and large number of variables,
values and filters that can be used, many view spectral processing
more as an art, rather than a science. Different perspectives
or different personal thresholds on what is a “good looking”
NMR spectrum can potentially lead to very different results
regarding what compounds are identified or which compounds
are accurately quantified in a biofluid spectrum. To address
this issue, BAYESIL itself performs all of the spectral processing
functions: starting from the FID, it performs zero-filling, Fourier
and Hilbert transformation, phasing, baseline correction, chem-
ical shift referencing, reference deconvolution and smoothing.
Automating this process ensures reproducibility, consistency and
uniformity of the input data prior to spectral deconvolution. Here
we briefly sketch some of the more challenging steps in this
process.
Phasing involves maximizing the symmetry of the peaks by
reducing zero-order and first-order phase mismatch. Zero-order
phase mismatch is a sign of the difference between the reference
phase and the receiver phase and is independent of frequency.
The first-order phase mismatch can be a result of the time-delay
between excitation and detection, flip-angle variation and the
filter that is used to reduce the noise outside of the spectral
bandwidth [15]. In addition to using well-known techniques,
such as spectral norm minimization [16], BAYESIL uses the
cross entropy optimization method [11] to jointly maximize a
direct measure of peak symmetry for isolated peaks across the
spectrum.
Baseline correction involves removing distortions that may
arise from hardware artifacts or highly concentrated compo-
nents of the mixture (e.g., solvent), while keeping the desirable
signal intact. This process is often performed in two steps: 1)
baseline-detection and 2) modelling. BAYESIL relies on iterative
thresholding [17] and estimating the signal-to-noise ratio to detect
the baseline points. It uses monotonic cubic Hermite interpolation
[18] and Whittaker smoothing technique for baseline modelling
[19].
BAYESIL also provides the options for smoothing and line-
broadening using Savitzky-Golay [20] and Gaussian filters. How-
ever smoothing is mostly cosmetic and it is not essential for
spectral deconvolution. In fact, it may degrade the signal and
occasionally remove the the low-amplitude and narrow peaks.
Similarly, we found the effect of reference deconvolution – which
may be used to remove instrumental or experimentally induced
distortions of the Lorentzian lineshape – is also mostly cosmetic,
and if the distortion around the reference peak has any source
other than poor shimming, using reference deconvolution will
have an adverse effect on the rest of the NMR spectrum.
3B. Spectral Deconvolution
An NMR spectrum for a compound M is a collection of one
or more Lorentzian peaks formed into one or more clusters –
that is, each compound M is a set of clusters {Ck}, where each
cluster Ck is set of peaks, and each peak is defined by a triple,
θ = (θ1, θ2, θ3) corresponding to its height, center and width (at
half height) respectively – where the height at x due to this peak
is q(x;θ) = θ1θ3
θ3+4(θ2−x)2 . Letting X refer to the entire spectrum
(e.g., from -1 to 13 PPM when referenced against the DSS peak),
the height of the spectrum of a pure compoundM at each location
x ∈ X , is
ŝ(x ;M, ρM, δM) = ρM
∑
C∈M
∑
θ∈C
q(x− δC ;θ) (1)
where ρM is the concentration of this compound and δM =
{δC | C ∈ M} is the set of chemical shifts for the clusters associated
with this compound.
An NMR spectrum is essentially a linear combination of the
peaks in its component compounds: that is, the height at each
PPM value x of a mixture spectrum is just the sum of the contribu-
tions of each compound. This means, given the concentrations of
the compounds ρ = {ρM}, and the chemical shifts δ = ⋃M δM
of the clusters associated with these compounds, we can then
“draw” an NMR spectrum – i.e., the height at each PPM x, given
this ρ and δ, is ŝ(x ;ρ, δ) =
∑
M ŝ(x ;M, ρM, δM).
The spectral deconvolution challenge, in general, is the reverse
process: Given a set of compounds {M1, . . . ,Mr} with associated
signatures (i.e., θ values of their peaks, organized in clusters)
and the observed spectrum s(·), find the “best” combination of
concentrations ρ and shifts δ to fit that spectrum. To determine
which values are best, for now, we consider a simple loss
function that is the (square of the) difference of the heights
between the observed spectrum s(·) and the reconstructed
spectrum ŝ(· ; δ,ρ)
`X ( s(·), ŝ(· ;ρ, δ) ) =
∫
x∈X
(
s(x)− ŝ(x ;ρ, δ) )2 dx (2)
where the subscript X indicates that this loss function applies to
the entire spectrum; see Appendix II for BAYESIL’s actual loss
function.
Our task is to find the values of
[ρ∗, δ∗] = argρ,δmin `X (s(·), ŝ(· ;ρ, δ)) (3)
that minimize this loss function. Figure 1 shows part of a spec-
trum over a complex mixture, and BAYESIL’s solution obtained
by minimizing the loss function.
This corresponds to search over a huge space – all possible
shifts for each of the clusters, and all possible concentrations
over the compounds. The key innovation of BAYESIL is how
it minimizes this highly non-linear loss function, efficiently. In
particular, BAYESIL “factors” this large task into a set of inter-
related smaller tasks. Two characteristics of the NMR spectra
make this factorization possible: 1) each shift is over only a small
range (typically a window of ±0.025 PPM); and 2) as the height in
the spectrum due to a Lorentzian peak diminishes quadratically
from its center, each peak and therefore each cluster can only
“influence” a small interval; see Appendix III.
Now consider a function that maps each point in the spectrum
to the set of clusters that might affect the height at this location.
That is, given the set of compounds {M} that might appear in a
particular biofluid (e.g., the 48 that can appear in CSF), we can
identify each PPM location x ∈ X with the small set of clusters
that might influence it, C(x).
We can then partition the spectrum into disjoint contiguous
regions, {XI}, where every PPM location in each XI involves
exactly the same subset of clusters – i.e., for any pair of points
x1, x2 ∈ XI , we know that C(x1) = C(x2). For example, our
library for CSF includes 48 compounds, with a total of 180
clusters and 946 peaks. A typical CSF spectrum is partitioned into
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Fig. 2. Partitioning of X into continuous blocks XI ⊂ X for a part of a
human serum spectrum. Here each block is shown with a different shade of
blue, below the horizontal axis. The domain of influence of each cluster is
also indicated with coloured blocks.
∼350 regions. Each of these regions will involve between 1 and
∼25 clusters, and span between 0.0001 and 1.5 PPM. Moreover,
each cluster will appear in between 1 and ∼70 different regions.
Figure 2 shows the division of a part of human serum NMR
spectrum into regions XI ; blocks in different shades of blue.
For example the region X[.8563,9289] from 0.8563 to 0.9289 PPM
might include significant contributions from the first cluster of 2-
Hydroxybutyrate, the first cluster of L-Isoleucine and/or the first
cluster of L-Leucine. The region immediately to its left (from
0.9289 to 0.9370 PPM) includes these and also a cluster of L-
Valine, and the one to the right (from 0.8563 to 0.87526 PPM)
does not include L-Isoleucine.
As the loss function `(·, ·) is additive over the domain X , we
can rewrite the optimization of eq[3] as the sum of the losses for
each of the regions XI :
[ρ∗, δ∗] = argρ,δmin
∑
I
`XI
(
s(·), ŝ(· ;ρI , δI)
)
(4)
Now recall that each region XI involves relatively few compounds
and clusters. This suggests a preliminary step of simply “solving”
each region, by itself: i.e., find the best centers for the clusters
in that region δI , and the best concentrations for the associated
compounds ρI , which collectively minimize the loss over the PPM-
interval XI . This simple approach is fast, as it involves relatively
few variables and a limited range of PPM-values. Unfortunately,
this does not produce the overall correct answer – that is, each
region has an opinion about the concentration and shift values
of its cluster, and when two (or more) regions each involve the
same variable, they must both agree on its value.
To address this problem, we take a probabilistic approach,
viewing the task of minimizing the loss function eq[2] as finding
the “Maximum a Posteriori” (MAP) assignment – i.e., the assign-
ment to all of the cluster-shift and compound-concentration [δ,ρ]
variables that makes the observed data as likely as possible. Here,
the Boltzmann formula gives the probabilistic interpretation of
the loss (a.k.a. the energy)
P(ρ, δ | s(·) ) = 1
Z
exp
{
− 1
T
`X
(
s(·), ŝ(· ;ρ, δ) )} (5)
where Z is the normalization constant and T is known as the
“temperature” parameter, explained in Appendix IV. Using the
decomposition of loss over regions (eq[4]) we can write this
distribution in factored form
P(ρ, δ | s(·) ) = 1
Z
∏
I
fI(ρI , δI)
fI(ρI , δI) = exp
{
− 1
T
`XI
(
s(·), ŝ(.;ρI , δI)
) }
(6)
4Fig. 3. Factor-graph for a library of 15 compounds immediately below
an associated NMR spectrum. Each factor is represented by a square and
each variable using a circle. Concentration (larger circles) and shift variables
(smaller circles, beside the associated concentration) corresponding to each
compound appear together. The position of each factor fI position in the plot
corresponds to the center of the corresponding block XI .
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Fig. 4. A small region of human serum spectrum. The plots above horizontal
axis show the original spectrum (solid black), individual clusters as well as
overall fit (dashed red). The curves below horizontal axis show the BAYESIL’s
distribution over chemical shift variables for each cluster (C), over 6 iterations
of spectral deconvolution. The distributions become more peaked towards the
correct center in each iteration. Distributions below the horizon have the color
of their associated cluster.
This decomposition of the distribution P(ρ, δ | s(·) ) can be
represented using a probabilistic graphical model, known as a
factor graph [21], which is a graph with two types of nodes: 1)
factors (corresponding to regions or fI ), and 2) variables (here,
concentrations and chemical shifts). Each factor has arcs that
point only to its associated variables. Figure 3 shows a portion of
this factor-graph for a simple defined mixture of 15 compounds.
By formulating the spectral deconvolution problem as MAP
inference in a factor-graph, we have a variety of inference
techniques at our disposal [21]. BAYESIL uses a non-parametric
sequential Monte Carlo method [22] tailored to this inference
problem (see Appendix IV for details). Using a Gaussian distri-
bution around a set of particles (a.k.a. kernel density estimation)
BAYESIL represents a distribution over each concentration ρM
and shift variable δC . By reducing the temperature parameter,
these distributions are gradually narrowed in each iteration
until convergence, at which point the mode of the distributions
represent an approximate MAP assignment. Figure 4 shows the
evolution of distributions over the chemical shift variables over
6 iterations of spectral deconvolution.
C. BAYESIL’s Spectral Library
Key to the success of any spectral deconvolution algorithm is
the quality and size of its spectral library. We therefore collected
1D 1H NMR reference spectra for each of the compounds in
BAYESIL’s spectral library using pure compounds obtained from
the Human Metabolome Library [1], using a standard protocol
(see Materials and Methods). The spectral library contains rele-
vant information about each compound (M) including individual
peak clusters (C) and peak amplitude positions and widths (i.e., θ
in eq[1]), as well as allowable chemical shift window δC ≤ δC ≤ δC
for each cluster C.
To analyze each biofluid, BAYESIL uses a specific spectral sub-
library – here, one for serum and another one for CSF. The
serum library consists of 50 NMR-detectable compounds from the
human serum metabolome [23] while the CSF library consists
of the 48 NMR-detectable compounds from the human CSF
metabolome [24]; see Appendix V. The use of biofluid-specific
or organism-specific spectral libraries significantly improves the
performance of the spectral fitting process as it reduces the
number of possible explanations for each peak.
II. ASSESSMENT
BAYESIL was assessed using 3 different types of spectral data
sets over two different types of biofluids:
(a) Computer generated mixtures derived from its spectral
library. We generated 5 random serum and 5 random CSF
spectra by sampling from the distribution of the measured
concentration ranges of various compounds, and the probability
of observing them in the mixture from [23], [24]. The chemical
shifts were also randomly sampled according to the chemical
shift ranges from the corresponding spectral libraries. To be
more realistic, we also added a small amount of noise to the
spectrum – independently to the height at each position x ∈ X .
These correspond to “perfect” spectra, and are intended to assess
the robustness and performance limits of BAYESIL under optimal
conditions.
(b) Defined mixtures prepared in the laboratory. We created 15
defined mixtures (5 defined mixture of serum, 5 defined mixture
of CSF, 5 random mixture of compounds in both serum and
CSF, involving > 60 compounds), using carefully measured pure
compounds and freshly prepared solutions. These provide real
spectral data that probably include common spectral and solution
artifacts (baseline and phasing issues, minor spontaneous reaction
products, contaminants, matrix or pH effects). This set was used
to assess BAYESIL’s performance under well-controlled conditions
where the composition and of the mixtures was almost perfectly
known.
(c) Biological serum and CSF samples. We took human CSF and
serum samples from previously studied samples that had been
analyzed and quantified by NMR experts – here, 50 human serum
and 5 human CSF samples. The set of compound mixtures was
used to assess BAYESIL’s performance under realistic conditions
with common spectral and solution artifacts. Although human
CSF contains a smaller number of NMR-detectable compounds
than human serum, it is more difficult to profile due to the
lower concentration of metabolites. While both the biological
samples and defined mixtures were thoroughly analyzed, their
exact compound concentrations cannot be perfectly known.
Overall, we believe these 3 test sets provide a robust assessment
of BAYESIL’s performance (as well as its limitations) under a
wide range of conditions.
BAYESIL estimates the “detection threshold” based on the
signal to noise ratio (SNR) in each spectrum – i.e., when the
signal is noisy this threshold is increase to provide a more
confident identification and quantification. The SNR and therefore
the detection threshold is directly related to the number of
scans during spectral acquisition. For example our biological
serum samples are produced using 128 scans and therefore most
detection thresholds are ∼ 10µM. Since compound concentra-
tions in our CSF samples are considerably lower than serum,
their analysis requires higher quality spectra (see Materials and
Methods). Our CSF samples use 1024 scans resulting in detection
thresholds that are often less than 2µM. However this threshold
5TABLE I
IDENTIFICATION AND QUANTIFICATION ACCURACY OF BAYESIL AND HUMAN EXPERT ON VARIOUS DATA-SETS.
serum CSF complex
biological def. mix. comp. gen. biological def. mix. comp. gen. def. mix.
BAYESIL
id. accuracy .93± .04 .94± .02 .98± .01 .90± .04 .89± .03 .95± .03 .90± .02
quant. accuracy .89± .02 .90± .02 .98± .01 .91± .01 .90± .02 .94± .02 .88± .02
expert id. accuracy - - .91± .02 - - .87± .05 -quant. accuracy - - .95± .01 - - .91± .04 -
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Fig. 5. (left) BAYESIL’s true/false positive/negative rate in identification of
individual compounds in 50 biological serum samples. (right) The average
concentration for correctly identified compounds in the same samples. The
error bars show the average difference between BAYESIL and expert values
for each compound and the red dots show the detection threshold for each
compound.
is not uniform across metabolites. BAYESIL also uses a relative
factor in compound detectability; as some compound such as
Choline are easy to identify and quantify at low concentrations
while for some other compounds such as L-Asparagine, experts
use a higher detection threshold.
Given a spectrum of a mixture of compounds (with “true”
concentrations {ρM}), BAYESIL returns its estimates of these
concentrations {ρ̂M}, which might be 0 if that compound is
absent. We say a compound is a true positive if both ρ̂M and
ρM are positive – that is, greater than the detection threshold,
and a true negative if both ρ̂M and ρM are less than the
threshold; in either case, BAYESIL’s prediction is considered
correct. BAYESIL’s identification accuracy for a given spectrum
is the ratio of correct labels (true positives plus true negatives)
to the library size. BAYESIL’s “quantitative accuracy” describes
how often its estimates ρ̂M were “close enough” to the true values
ρM; note that simply computing |ρ̂M−ρM| is not enough as this
measure would basically only consider the compounds with high
concentrations. We instead use the medianM
( |ρM−ρ̂M|
max(ρ̂M,ρM)
)
as a
measure of the percentage error in concentrations. Table I reports
BAYESIL’s identification and quantification accuracies, for each
of the tasks listed above. For the biological and synthetic samples,
we assume the human expert’s assessment is correct.
Figure 5(left) reports the frequency of false/true posi-
tives/negatives for individual compounds in 50 serum samples.
Figure 5(right) shows the average of ρM for correctly identified
compounds in 50 serum samples, as reported by NMR experts,
the average detection threshold for diffent compounds as well as
the average difference ρ̂M− ρM, between BAYESIL and expert’s
estimate for each compound.
These results on a diverse set of test data suggest that
BAYESIL is often within 10% of the expert’s estimate, and
where the ground truth is known, BAYESIL’s metabolic profile
is often more accurate than the expert’s. BAYESIL’s web-page
http://www.bayesil.ca provides a complete description of all of the
studies reported above, showing the fits and the metabolic profiles
obtained.
A. Efficiency
On a single 2.8 GHz CPU processor, BAYESIL typically takes
less than 5 minutes to profile a serum or CSF spectrum. Over
a sustained 24 hour period, BAYESIL should be able to process
more than 200 spectra (vs. ∼20 spectra/day for a human expert)
and accurately identify-&-quantify approximately 50 compounds
per spectrum. This corresponds to an output of more than 5000
metabolite measurements a day for a single CPU. It is possible to
produce profiles yet faster by reducing the number of particles
used in BAYESIL’s deconvolution process: reducing this by a
factor of 10, reduces the run-time to less than one minute.
This speed-up often reduces the identification and quantification
accuracy by only 5-10%.
B. Limitations
A key disadvantage of NMR analysis (versus mass spec), in
general, is that NMR is relatively insensitive, with a lower limit
of detection of ∼ 1− 5 µM and a requirement of relatively large
sample sizes (∼ 500µL). For high-quality spectra with high SNR,
such as CSF samples in our study, BAYESIL is often able to
achieve its high accuracy within these detection limits.
Key to the high level of performance of BAYESIL is the
use of biofluid-specific spectral libraries in its spectral fitting
routines (a.k.a. targeted profiling). Without these, BAYESIL would
be substantially slower and less accurate in both identification
and quantification. Therefore users must provide BAYESIL with
information about the biofluid being analyzed. Obviously, the
mis-identification or mislabelling of a biofluid sample could lead
to somewhat poorer results.
This need for prior knowledge about the typical composition of
biofluid mixtures has motivated us, and others, to spend consid-
erable efforts to determine the NMR-detectable metabolomes for
many biofluids, including human plasma/serum, cerebrospinal
fluid, saliva and urine (e.g., [23], [24], [25]), milk and rumen
(e.g., [26]), cell extracts (e.g., [27]), cancer cells [28], [29], and
many other fluids or extracts.
C. Other systems
There have been a number of software packages recently
developed to facilitate spectral profiling and compound iden-
tification/quantification by NMR; see Appendix I for details.
However, they do not seem to be particularly accurate on real
biofluids. Furthermore, many of the packages are not currently
publicly available. To date, the largest number of metabolites that
has been automatically identified and quantified using publicly
available software is 26 compounds, by BATMAN [13]. However,
an analysis of this magnitude required several hours of CPU
time to process a single spectrum. Furthermore, BATMAN also
requires a human expert to perform many of the preliminary
steps. We compared BAYESIL to BATMAN on simple computer-
generated mixtures, involving 5, 10 and 20 compounds selected
from BATMAN’s library, as well as a preprocessed human serum
sample. For the computer generated spectra, both BATMAN and
BAYESIL used identical libraries containing only the relevant
compounds. BATMAN achieved 85−87% quantification accuracy
for the computer-generated mixtures but took 2-9 hours to run,
while in all cases BAYESIL achieved > 98% accuracy in less than
63 minutes. For the serum spectra, BAYESIL used a library of 50
compounds, while BATMAN used a subset of 40 compounds that
its library has in common with the serum metabolome. BATMAN
took 19 hours to analyze the serum spectrum and identified all
the compounds in its library (resulting in 85% identification
accuracy) and only 8% quantification accuracy compared to
BAYESIL which took 5 minutes to achieve 98% identification
and 90% quantification accuracy.
CONCLUSION
NMR is a particularly appealing platform for conducting
metabolomic studies on biofluids as it is a rapid, robust, highly
reproducible, non-destructive, and fully quantitative technique
that requires no prior compound separation or derivatization.
The main barrier preventing widespread adoption of NMR-
based metabolomics in industrial or clinical applications is the
requirement for manual spectral profiling. BAYESIL addresses
this critical problem by providing fully automated spectral
processing and deconvolution. Furthermore it is able to perform
this task on mixtures containing > 50 compounds, with 90%
accuracy. We believe that removing the automation barrier will
have a significant, positive impact on NMR spectroscopy and
NMR-based metabolomics. BAYESIL is freely available for users
to perform metabolic profiling of 1D 1H NMR spectra of serum,
CSF and other biofluid mxitures (excluding urine) collected at
500 and 600 MHz.
III. MATERIALS AND METHODS
To produce each of the reference spectra for BAYESIL’s library,
we first prepared stock solutions (1 mM to 100 mM) for each
compound in 1 L in volumetric flasks. The metabolites were
dissolved in 20 mM NaHPO4 (pH 7.0). These stock solutions
were further diluted if necessary to obtain a final stock solution
concentration of 1 mM. The final sample for NMR was prepared
by transferring 1140 µL to a 1.5 mL Eppendorf tube followed by
the addition of 140 µL D2O and 120 µL of the reference standard
solution (11.67 mM DSS (disodium-2,2-dimethyl-2-silapentane-5-
sulphonate), 20 mM NaHPO4, pH 7.0). After confirming that the
pH of the sample was between 6.8 and 7.2 (adjusting the buffer
if necessary), we transferred 700 µL to a standard NMR tube for
spectral acquisition. All library 1H NMR spectra were collected
on both 500 MHz and 600 MHz Inova spectrometers equipped
with 5 mm Z-gradient PFG probes. A standard presaturation
1H-NOESY experiment(tnnoesy.c) was acquired at 25oC using
the first increment of the presaturation pulse sequence. A 4 s
acquisition time, a 100 ms mixing time, a 10 ms recyle delay and a
990 ms saturation delay were chosen. Thirty-two transients were
acquired for samples collected at 600 MHz while 128 transients
were acquired for all samples collected at 500 MHz. Eight steady
state scans were employed and the presaturation pulse power was
calibrated to provide a field width no greater than 80 Hz. Both
the transmitter offset and the saturation pulse were centered on
the water resonance and no suppression gradients were used.
After spectral collection, the spectra were checked for quality
and then analyzed using a locally developed spectral analysis tool
to convert the spectra into a series of XML files. In producing
the XML library, most peak clusters were given a default shift-
window of 0.025 ppm, with the exception of few compounds
such as histidine or citrate that are known to be highly pH-
sensitive. Both the synthetic and real biological spectral data were
collected in the manner described above except for biological CSF
in which 1024 scans were collected to compensate for dilution.
For sample preparation, CSF was used as is, while serum was
obtained after the blood had clotted for 30 min at 25oC and then
passed through pre-rinsed 3000 MWCO Amicon Ultra-0.5 filters
to remove remaining proteins. In each case 285 µL of filtrate
was obtained and 35 µL of D2O and 30 µL of buffer was added.
A total of 350 µL was then transferred to a suitable Sigma tube
for NMR data acquisition. In the case of biological CSF, where
less than 285 µL was obtainable, the samples were diluted with
sufficient H2O.
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8APPENDIX
I. OTHER NMR-ANALYSIS SOFTWARE TOOLS
Several software packages have been developed to facilitate
NMR spectral processing, compound identification and quan-
tification. While some facilitate two dimensional NMR spectral
processing and compound identification (e.g., [1], [2], dataChord
(One Moon Scientific)), none are completely automated and
provide compound quantification. Furthermore, because modern
metabolomic NMR studies require the analysis of a tremendous
amount of spectral data, the time required to collect 2D NMR
spectra makes their implementation prohibitive not only due
to their inherent inability to facilitate high-throughput studies
but also due to complicating factors such as sample degradation
within the spectral acquisition time frame. Thus, more effort has
been directed at developing software tools for 1D NMR.
Some tools provide basic processing functionalities [3], [4].
(In fact, BAYESIL uses NMR-GLUE [3] for handling different
input/output data formats.)
We focus on software package capable of handling high-
throughput 1D metabolomic NMR data. An ideal tool here should
have the following features: (1) fully automated – in both spec-
tral processing and compound identification and quantification;
(2) flexible and customizable – capable of analyzing a wide (and
extendable) range of different biological fluids; (3) ubiquitous –
can accommodate input from different NMR vendors, multiple
spectrometer frequencies; and of course (4) accurate.
Various software packages have made incremental steps to-
ward achieving these goals. Of the 19 that we could identify, only
a handful provide some degree of automated identification and/or
quantification (1): [1], [5], [6], [12], [8], [10], [12], Juice Screener,
Wine Screener and Metabolic Profiler (Bruker Corporation) and
Chenomx NMR Suite (Chenomx Inc.). This task (of spectral
deconvolution and metabolite profiling) has been tackled with
a variety of algorithmic approaches – including simple text file
matching, binning [5], principal component analysis and non-
negative matrix factorization [1], [6], combinations of simulated
annealing and gradient descend ([7], Chenomx NMR Suite
(Chenomx Inc.)), cross entropy method [8] and Monte Carlo
techniques [10]. However only a few of these softwares provide
automated spectral processing ([11],Juice Screener and Wine
Screener).
In terms of flexibility and customizability (2), some software
packages do utilize large data-sets (HMDB [14], BMRB [15] or
MMCD [16]) but they still require the user to select a subset
of the compounds, and/or do not provide quantification [1], [9],
[2]. Others are specialized to particular mixtures ([11], Wine
Screener, Juice Screener and Vantera (LipoScience Inc.)) and
none can accurately quantify complex mixtures (with > 50
compounds). Moreover, many of these software packages are
specific to a particular instrument (e.g., [10], [14], [12], [13],
Wine Screener, Juice Screener, dataChord and Vantera).
It is often difficult to access accuracy (4), as the descriptions
of many software tools do not provide any assessment (e.g., Juice
Screener, Wine Screener and Metabolic Profiler (Bruker Corpo-
ration), [1], [11]) and many systems have been assessed merely
on very simple mixtures (e.g., [2], [9], [10],lipoprofiler/Vantera
(LipoScience Inc.)) or simple spike-in experiments [5], [12], [13].
To summarize, BAYESIL is the only 1D 1H NMR interpretation
system that is completely automated (both preprocessing and
deconvolution) for a wide range of complex mixtures (i.e.,
all mammalian biofluids covered by its current library; see
www.bayesil.ca), involving > 60 compounds. Moreover, it is
efficient, general, accurate and publicly available.
APPENDIX
II. BAYESIL’S LOSS FUNCTION
In the manuscript, we described a simple sum of squared error
loss function (eq[2]) to explain the basic ideas behind BAYESIL’s
spectral deconvolution. In practice BAYESIL uses a more com-
plicated loss function that also penalizes the derivatives of the
difference between the given spectrum s(·) and its reconstruction
ŝ(· ;ρ, δ):
`X (s(·), ŝ(· ;ρ, δ)) =
∑
c∈{0,1,2,3}
γc
∫
X
(
∂c
∂xc
(s(x)−ŝ(x ;ρ, δ))
)2
dx
where the integral for c = 0 corresponds to sum of squared
errors (eq[2]), and c ≥ 1 enforce the smoothness of the difference
between s(·) and ŝ(·). Here, the scalars γc weight the relative
importance of these terms. Similar to the sum of square errors,
this loss function also decomposes over the regions XI , allowing
for the same kind of factor-graph representation.
APPENDIX
III. DETAILS ABOUT THE CONSTRUCTION OF NMR
SPECTRAL REGIONS
The construction of the spectral regions is based on the
observation that the influence of each peak (and hence of each
spectral cluster) is significant over only a relatively small region
of the spectrum. To estimate this “region of effect” for each
cluster, BAYESIL first obtains an upper-bound ρM ≥ ρM on
the concentration of each compound. This upper-bound is also
used in performing approximate inference (see Appendix IV).
For each compound M, this is the minimum of the upper-bounds
obtained using each of its clusters C ∈M: ρM = minC∈M ρC . The
upper-bound from each cluster (ρC) is obtained by progressively
shifting the signature for that cluster under the spectrum and
finding the maximum value that it can take, assuming all the
other compounds and clusters are absent:
ρC = max
δC
min
x
s(x)
sC(x; 1, δC)
where sC(., 1, δC) is the signature of cluster C as defined by the
set of all its peaks (see eq[1]) assuming a unit concentration and
allowing δC to vary in a small window [δC , δC ] around the center
defined by the library.
Now that we have an upper-bound on concentrations, using an
example from Figure 2 (in the main manuscript) we show why
the region of effect for each cluster is bounded. In this figure,
the center (δL−Isolucine(1)) for the first cluster of L-Isoleucine
can only appear in the interval [0.9130, 0.9380] PPM; as its
concentration is at most ρL−Isoleucine = 95µM, its contribution
to any point outside [.8563, .9954] will be five times less than the
estimated noise-level of this spectrum, where the noise-level is
estimated as the standard deviation of the spectrum s(·) over all
of the baseline points. We can therefore identify this L-Isoleucine
cluster with the interval [.8563, .9954]. Note this cluster includes
3 peaks. In general, the range of a cluster spans the set of peaks
that it contains.
APPENDIX
IV. DETAILS OF BAYESIL’S APPROXIMATE INFERENCE
This appendix provides details of BAYESIL’s inference proce-
dure, using the factor-graph representation of the problem.
Recall that ρI and δI denote the set of shift and concentration
values for all the clusters and associated compounds that can
appear in the region XI ; we let µI = [ρI , δI ] denote the set
of variables of both both types. Since the loss function `(·, ·) is
additive over domain the X , we can rewrite the optimization of
eq[3] in exponential form as:
µ∗ = argµmax
∏
I
fI(µI)
fI(µI) = exp
{
− 1
T
`XI ( s(·), ŝ(.;µI) )
}
(7)
9where each factor fI is basically the exponential of the negative
loss function (−`XI ) over the region XI and T is the temperature.
Here a factor node fI is connected to all of its associated variables
µi ∈ µI in the factor-graph; see Figure 3. In the following, we
use ∂µi = {fI | µi ∈ µI} to refer to all the factors that are
adjacent to variable µi in the factor-graph.
Inference in this factor-graph is challenging as its factors can
each depend on a large number of continuous variables. This
means that the most basic task of (conditional) sampling from a
factor is unfeasible and we cannot use Glauber dynamics (e.g.,
[18]). This is further complicated by multi-modality of the factors,
which prevents the use of parametric densities and inference
techniques such as Gaussian Belief Propagation [21] or (primal
and dual) decomposition methods that require convex sub-
problems [17]. BAYESIL uses a non-parametric sequential Monte
Carlo method that is closely related to sequential importance
sampling and particle filters. The following is a step-by-step
explanation of this inference procedure.
BAYESIL models a distribution P(µi) over individual variables,
non-parametrically: as a set of “particles”. These particles, µi[n]
for 1 ≤ n ≤ N , collectively serve to approximate the target
distribution. In all the experiments described in the manuscript
we use N = 10, 000 such particles, however using a larger
number can increase accuracy at the cost of increased run-time.
For each n, the joint set of particles for all variables,
µ[n] = [ρ[n], δ[n]], corresponds to a complete spectrum – i.e.,
ŝ(x ;ρ[n], δ[n]) =
∑
M ŝ(x ;M, ρM[n], δM[n]) – which means
we can compute its loss (eq[2]). BAYESIL calculates the loss for
each region XI , fI(µI [n]) (eq[7]). Since each variable µi appears
in many regions ∂µi, we can “credit” each assignment µi[n]
with the loss over all such regions. This allows us to compute a
“weight” for each variable µi and for each particle n. BAYESIL
then uses these weighted sets of particles to produce a new
distribution for the variable µi, one that prefers values that have
less loss. BAYESIL then iterates, using this new distribution, until
convergence.
More specifically, BAYESIL first assigns each of the variables µi
to an initial distribution of values P(0)(µi) – e.g., δL−Isoleucine(1)
is drawn uniformly from its chemical shift range [0.9130, 0.9380]
PPM, and ρL−Isoleucine(1) is drawn uniformly from its range [0,
95] µM (see Appendix III for the procedure to estimate the upper
bound ρL−Isoleucine(1) = 95µM). It then iterates t = 0, 1, 2, ...
over the following four steps:
Step1: It draws N =10,000 particles from each P(t)(µi) indepen-
dently, producing 10,000 complete assignment to these variables
µ(t)[n] = [ρ(t)[n], δ(t)[n]] (for n = 1, 2, ...,10,000), from its
current product distribution.
Step2: For each joint particle µ(t)[n]: For each factor I , BAYESIL
computes the loss associated with this region, `I(µI [n]
(t)), and
then fI(µI [n]
(t)) using eq[7].
Step3: Recall each variable µi belongs to a set of regions (each
corresponding to a factor), ∂µi. BAYESIL then implicitly identifies
µi[n]
(t) with the loss associated with all corresponding regions.
This is achieved by defining a weight
ω(µi[n]
(t)) ∝
∏
fI∈∂µi fI(µI [n]
(t))
P(t)(µi[n](t))
(8)
where P(t)(·) is the distribution used for sampling – i.e., impor-
tance sampling weight.
Step4: Finally, BAYESIL produces a “new” distribution for each
variable µi, using kernel density estimation (KDE) over a
weighted set of the N particles µ[n](t) 1 ≤ n ≤ N to represent
the marginal distribution P(t+1)(·) over each variable µi ∈ µ:
P(t+1)(µi) ∝
N∑
n=1
ω(µi[n]
(t)) k
(
µi − µi[n](t)
h
)
where k(·) is a kernel function (e.g., a Gaussian) and the kernel
bandwidth h is estimated from the data (e.g., [19]).
BAYESIL then checks for convergence; if convergence occurs, it
returns the mode of individual distribution as its approximation
to the MAP assignment. If not, it returns to Step1.
Note the temperature parameter T (used in eq[7] which
appears in eq[8]) is gradually reduced from a large value towards
zero per iteration. Figure 4 is basically showing the evolution
of KDEs over the chemical shift variables (P(t)(δC) for t ∈
{1, . . . , 6}) over 6 iterations of spectral deconvolution.
In practice, BAYESIL ignores the importance sampling weights.
This biases P(t+1)(µi) towards P(t)(µi), but significantly reduces
the variance and the computation time. Since we are interested
in the mode (rather than the marginals) of P(µi), this trade-off is
favourable, as the bias of the previous estimate is mostly towards
more probable assignments.
APPENDIX
V. LIST OF NMR-DETECTABLE COMPOUNDS IN SERUM
AND CSF
Our serum library includes the following metabolites plus DSS:
1-Methylhistidine, 2-Hydroxybutyric acid, Acetic acid, Betaine,
Acetoacetic acid, L-Carnitine, Creatine, Citric acid, Choline,
Ethanol, D-Glucose, Glycine, Glycerol, Formic acid, L-Glutamic
acid, Hypoxanthine, L-Tyrosine, L-Phenylalanine, L-Alanine, L-
Proline, L-Threonine, L-Asparagine, L-Isoleucine, L-Histidine,
L-Lysine, L-Serine, L-Lactic acid, L-Aspartic acid, L-Cystine, Or-
nithine, Pyruvic acid, Succinic acid, Urea, 3-Hydroxybutyric acid,
L-Arginine, Creatinine, L-Cysteine, L-Glutamine, L-Leucine,
Malonic acid, L-Methionine, Isopropyl alcohol, L-Valine, L-
Tryptophan, Acetone, Isobutyric acid, Methanol, Propylene gly-
col, Dimethyl sulfone.
Our CSF library includes the following compounds plus DSS:
2-Hydroxybutyrate, 2-Oxoisovalerate, 3-Hydroxyisobutyrate, Ac-
etate, Ascorbic acid, Acetoacetate, Creatine, Dimethylamine,
Citrate, Choline, Glucose, Glycerol, Formate, Glutamate, Ty-
rosine, Phenylalanine, Alanine, Threonine, Mannose, Isoleucine,
Histidine, Lysine, Serine, Lactate, 2-Oxoglutarate, myo-Inositol,
Oxalacetate, Pyruvate, Succinate, Pyroglutamate, Xanthine,
Urea, 3-Hydroxybutyrate, 2-Hydroxyisovalerate, Creatinine, Glu-
tamine, Fructose, Leucine, Methionine, 3-Hydroxyisovalerate,
Isopropanol, Valine, Tryptophan, Acetone, Methanol, Propylene
glycol, 1,5-Anhydrosorbitol, Dimethylsulfone.
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